Free · No account required · Powered by AI across the world's largest grants + funders database
Currently focused on US federal, state, and foundation grants.
This funding opportunity is designed to support research in understanding how to engineer intrinsic characteristics of stem cell-derived islet cell products that can result in improved cell replacement therapy outcomes. Unlike cadaveric human islets, stem cell-derived islet cell products are generated from well-defined and highly controlled cell bank sources. Their banking, manufacturing, and quality control processes can be used to instill optimized cell characteristics resulting in more resilient and durable graft viability and function. This funding opportunity aims to stimulate studies on targets and pathways amenable to such engineering approaches and to encourage preclinical testing and validation of such strategies.This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.
Funding Opportunity Number: RFA-DK-26-306. Assistance Listing: 93.847. Funding Instrument: G. Category: HL. Award Amount: Up to $500K per award.
Based on current listing details, eligibility includes: Eligible applicants: State governments; County governments; City or township governments; Special district governments; Independent school districts; Public and State controlled institutions of higher education; Native American tribal governments (Federally recognized); Public housing authorities / Indian housing authorities; Native American tribal organizations (other than Federally recognized); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; For-profit organizations other than small businesses; Small businesses; Others (see text field entitled Additional Information on Eligibility for clarification). Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. This new requirement was effective, May 1, 2025.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors. Applicants should confirm final requirements in the official notice before submission.
Past winners and funding trends for this program
The goal of this Notice of Funding Opportunity (NOFO) is to accelerate the establishment ofeffective and reliable biomarkers of Alzheimers disease (AD) and AD-related dementias (ADRD) for usein therapy/medical product discovery and development, clinical trials and/or clinical practice. Specifically, this NOFO willsupport analytical and/or clinical validationof a biomarker, composite biomarker or biomarker signature, withrigor comparable with the expectations described in the Food and Drug Administration (FDA)Biomarker Qualification Program (BQP) or recommended by other FDA regulatory pathways. Funding Opportunity Number: PAR-25-209. Assistance Listing: 93.866. Funding Instrument: CA. Category: HL.
This is a Notice of Funding Opportunity (NOFO) for a Single Source that invites a recipient organization funded under the Electronic Medical Records and Genomics (eMERGE): Genomic Risk Assessment and Management Network Coordinating Center (RFA-HG-19-015) to participate in the Outcomes of Electronic Medical Records and Genomics (eMERGE) Genomic Risk Assessment and Management Network. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application will be peer-reviewed, and only meritorious applications will be considered.The NHGRI is announcing its intent to issue a single source cooperative agreement award to Vanderbilt University Medical Center to continue coordination of the eMERGE Risk Assessment Network. The eMERGE Network will extend through April 2030 follow-up and collection of outcome data on the roughly 25,000 patients receiving genomically informed risk assessment (GIRA) and management recommendations. Funding Opportunity Number: RFA-HG-26-008. Assistance Listing: 93.172. Funding Instrument: CA. Category: HL. Award Amount: Up to $687K per award.
Rural Communities Opioid Response Program (RCORP) - Impact is sponsored by Health Resources and Services Administration (HRSA). Funds community capacity building for prevention, treatment, and recovery services for substance use disorders in rural areas. Application snapshot: target deadline February 23, 2026; published funding information $200,000 - $1,000,000; eligibility guidance Rural organizations and communities addressing opioid response Use the official notice and source links for final requirements, attachment checklists, allowable costs, and submission instructions before applying.
Bloomberg Initiative to Reduce Tobacco Use Grants Program is sponsored by Bloomberg Family Foundation Inc.. This program supports projects to develop and deliver high-impact, evidence-based tobacco control interventions in low- and middle-income countries. Funding focuses on policy reforms such as strengthening tobacco taxation, implementing smoke-free laws, advertising bans, and graphic pack warnings. It includes both 'Open Rounds' for broad policy work and a specific 'Tobacco Industry Interference' (TII) subset to counter industry tactics. Geographic focus: Low- and middle-income countries (Global) Focus areas: Public Health, Tobacco Control, Policy Reform Official opportunity description and requirements excerpt: Contact | Bloomberg Philanthropies Strengthening Local Arts Organizations Connecting Audiences to Culture Online or Onsite Advancing the Arts Around the World Collaborating with Cultural Funders Expanding College Access and Success Supporting Career and Technical Education Supporting Educational Institutions Supporting Sustainable Cities Driving Sustainable Finance Spurring Innovation in Cities Strengthening City Data to Improve Lives Promoting Healthy Food Choices Combating the Overdose Epidemic Increasing Access to Reproductive Health Care Promoting Cardiovascular Health Building Public Health Coalitions Strengthening Health Data Women’s Economic Development Perelman Performing Arts Center at the World Trade Center Charlotte and William Bloomberg Medford Public Library Goldman Sachs 10,000 Small Businesses English French German Spanish Portuguese (Brazil) Italian Korean Russian Hindi Japanese Chinese (Simplified) Chinese (Traditional) English French German Spanish Portuguese (Brazil) Italian Korean Russian Hindi Japanese Chinese (Simplified) Chinese (Traditional) Bloomberg Philanthropies is only as strong as its connections. Whether you have questions or want to get involved, we want to hear from you. Please use the following information or fill out the form below to contact us and we’ll do our best to send you a prompt response. If your inquiry involves a request for funding or partnership, please note Bloomberg Philanthropies works with existing partners on all of our key initiatives and does not make grants outside our focus areas or directly to individuals. Grant proposals are by invitation only and news on grants competitions are posted regularly on our website. Members of the media may contact communications@bloomberg.org . Choose Your Subject General Inquiries Grants Events Careers Arts Education Environment Government Innovation Public Health Bloomberg Associates Founder's Projects Please note grant proposals are by invitation only and we do not make grants outside our focus areas or directly to individuals. Top photo: Christo’s temporary sculpture in Hyde Park, London, “The London Mastaba,” located in Serpentine Lake, Hyde Park during summer of 2018. Application snapshot: target deadline February 25, 2026; published funding information $50,000 - $250,000 per year; eligibility guidance Government agencies and non-governmental organizations (NGOs) in low- and middle-income countries (LMICs) as categorized by the World Bank. Priority is given to countries with the highest tobacco use. Use the official notice and source links for final requirements, attachment checklists, allowable costs, and submission instructions before applying.
Current published award information indicates Up to $500K per award Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is March 7, 2026. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
© 2026 Granted AI